, /PRNewswire/ -- The global uterine fibroid (UF) treatment device market size is estimated to grow by .03 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 9.
45% during the forecast period. Increase in healthcare expenditure is driving market growth, with a trend towards improving healthcare systems in emerging economies. However, high cost of treatment of uterine fibroid poses a challenge.
Key market players include Boston Scientific Corp., Conmed Corp., Gynesonics Inc.
, Hologic Inc., INSIGHTEC Ltd., and Co.
KG, Lumenis Be Ltd., Medtronic Plc, Merit Medical Systems Inc., Minerva Surgical Inc.
, Olympus Corp., and The Cooper Companies Inc..
Get a detailed analysis on regions, market segments, customer landscape, and companies- In the rapidly evolving healthcare landscape of emerging economies, the demand for medical devices, including uterine fibroid treatment devices, is increasing. Factors such as population growth, expanding middle class, and improving healthcare infrastructure are driving this trend. The BRICS countries, including , , , , and , represent significant opportunities for medical device manufacturers.
These economies, which account for over 50% of the global GDP, are experiencing a rise in gynecological diseases, including uterine fibroids. Sedentary lifestyles and obesity are contributing factors to the increasing prevalence of uterine fibroids. The expanding middle class in these countries is gaining access to priva.
